Want to see JP:177A full AI Analyst Report?
177A Stock Chart & Stats
¥1525.00
-¥17.00(-1.03%)
At close: 4:00 PM EST
¥1525.00
-¥17.00(-1.03%)
Day’s Range― - ―
52-Week Range¥841.00 - ¥2,020.00
Previous CloseN/A
Volume7.50K
Average Volume (3M)3.64K
Market Cap
¥4.40B
Enterprise Value¥4.81B
Total Cash (Recent Filing)¥2.49B
Total Debt (Recent Filing)¥2.19B
Price to Earnings (P/E)17.5
Beta0.75
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.62%
Share Statistics
EPS (TTM)49.05
Shares Outstanding5,111,600
10 Day Avg. Volume4,170
30 Day Avg. Volume3,643
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)1.04
Price to Sales (P/S)1.25
P/FCF Ratio-22.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)¥5.58B
Bulls Say, Bears Say
Bulls Say
Improving LeverageA falling debt-to-equity ratio meaningfully reduces financial risk and preserves financing flexibility. Over the next 2–6 months an improved leverage profile supports liquidity, lowers refinancing pressure, and gives management room to prioritize operations or strategic investments despite earnings softness.
Stronger Capital BaseA materially larger equity base provides a durable cushion against earnings volatility and supports balance-sheet resilience. This strengthens solvency, enables measured investment or partnering decisions, and reduces insolvency risk over a multi-month horizon even if operating results remain pressured.
Positive Operating Cash FlowSustained positive operating cash flow shows the core business generates cash, which is a durable indicator of cash-generative capacity. Even with negative free cash flow, positive operations cash provides time for management to adjust capex or working capital to restore FCF within several months.
Bears Say
Negative Free Cash FlowA material swing to negative free cash flow weakens funding autonomy and raises reliance on external financing or asset measures. Over 2–6 months this constrains reinvestment, increases balance-sheet vulnerability, and forces prioritization of cash conservation over growth or R&D activities.
Revenue DeclineA decline in revenue signals weakening demand or competitive pressure and reduces scale benefits. Persisting revenue contraction over the next few months will make margin recovery harder, limit operating leverage, and impair the company’s ability to stabilize cash flows without structural fixes.
Sharp Margin CompressionSevere margin erosion indicates rising costs or pricing pressure and materially lowers profitability and return on capital. If margins remain compressed for several months, the company will face diminished earnings quality and weakened ability to convert profits into sustainable cash, stressing long-term stability.
177A FAQ
What was Kohjin Bio Co.,Ltd.’s price range in the past 12 months?
Kohjin Bio Co.,Ltd. lowest stock price was ¥841.00 and its highest was ¥2020.00 in the past 12 months.
What is Kohjin Bio Co.,Ltd.’s market cap?
Kohjin Bio Co.,Ltd.’s market cap is ¥4.40B.
When is Kohjin Bio Co.,Ltd.’s upcoming earnings report date?
Kohjin Bio Co.,Ltd.’s upcoming earnings report date is Aug 14, 2026 which is in 25 days.
How were Kohjin Bio Co.,Ltd.’s earnings last quarter?
Kohjin Bio Co.,Ltd. released its earnings results on May 15, 2026. The company reported -¥5.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥5.6.
Is Kohjin Bio Co.,Ltd. overvalued?
According to Wall Street analysts Kohjin Bio Co.,Ltd.’s price is currently Overvalued.
Does Kohjin Bio Co.,Ltd. pay dividends?
Kohjin Bio Co.,Ltd. pays a Notavailable dividend of ¥10 which represents an annual dividend yield of 1.62%. See more information on Kohjin Bio Co.,Ltd. dividends here
What is Kohjin Bio Co.,Ltd.’s EPS estimate?
Kohjin Bio Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kohjin Bio Co.,Ltd. have?
Kohjin Bio Co.,Ltd. has 5,111,600 shares outstanding.
What happened to Kohjin Bio Co.,Ltd.’s price movement after its last earnings report?
Kohjin Bio Co.,Ltd. reported an EPS of -¥5.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.838%.
Which hedge fund is a major shareholder of Kohjin Bio Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:177A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kohjin Bio Co.,Ltd.
Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materials, including animal blood, sera, cell culture media, agar media for microbial assays, in-vitro diagnostic products, and cosmetics. Its extensive catalog for cell and tissue culture features specialized mediums crucial for virus and recombinant protein synthesis, hybridoma development, human lymphocyte cultivation, and insect cell lines. Additionally, Kohjin Bio supplies complementary items such as gas-permeable cell culture bags, cryopreservation agents, medium supplements, normal human cells along with their growth media, ES cell media, and comprehensive kits for in-vitro fertilization and early embryo culture. The firm further provides essential laboratory tools like cell separation solutions, physiological salt solutions, and a range of research reagents. Within microbiology, Kohjin Bio offers a wide array of culture media tailored for various applications. For clinical diagnostics, this includes mediums for identifying gram-positive cocci and gram-negative bacteria, susceptibility testing, general differentiation, anaerobic growth, and fungal detection, alongside tube mediums for confirmatory tests and expansion. For food safety, their products cover sterilization assessments, and the detection of E. coli, coliform bacteria, Staphylococcus spp., Bacillus cereus, and Vibrio parahaemolyticus. The company also produces mediums for total viable cell count determination and specific media for Campylobacter and fungi. The company's blood and serum division offers normal human blood, serum, and plasma, as well as pathological human serum. Its animal blood portfolio encompasses preserved, defibrinated, and hemolyzed animal blood, in addition to animal serum and plasma, with custom-designed formulations like Eagle medium also available. Beyond its manufacturing activities, Kohjin Bio engages in the breeding and distribution of laboratory animals, the sale of medical equipment, and provides contract services for animal immunization and antibody preparation. The company also manages the import and export of its diverse products and raw materials internationally.
Technical Analysis
StemRIM Inc.
―
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―